A novel soluble analog of the HIV-1 fusion cofactor, globotriaosylceramide (Gb3), eliminates the cholesterol requirement for high affinity gp120/Gb3 interaction

Radhia Mahfoud,† Murugesapillai Mylvaganam,‡ Clifford A. Lingwood,†,* and Jacques Fantini†,†*

Institut Méditerranéen de Recherche en Nutrition,* UMR-INRA 1111, Faculté des Sciences St-Jérôme, 1397 Marseille Cedex 20, France; Research Institute,† Hospital for Sick Children, Toronto; and Departments of Biochemistry and Laboratory Medicine & Pathobiology,§ University of Toronto, Canada

Abstract We have analyzed the interaction of adamantyl Gb3 (adaGb3), a semi-synthetic soluble analog of Gb3, with HIV-1 surface envelope glycoprotein gp120. In this analog, which was originally designed to inhibit verotoxin binding to its glycolipid receptor, Gb3, the fatty acid chain is replaced with a rigid globular hydrocarbon frame (adamantane). Despite its solubility, adaGb3 forms monolayers at an air-water interface. Compression isotherms of such monolayers demonstrated that the adamantane substitution resulted in a larger minimum molecular area and a more rigid, less compressible film than Gb3. Insertion of gp120 into adaGb3 monolayers was exponential whereas the gp120/Gb3 interaction curve was sigmoidal with a lag phase of 40 min. Adding cholesterol into authentic Gb3 monolayers abrogated the lag phase and increased the initial rate of interaction with gp120. This effect of cholesterol was not observed with phosphatidylcholine or sphingomyelin. In addition, verotoxin-bound adaGb3 or Gb3 plus cholesterol was recovered in fractions of comparable low density after ultracentrifugation through sucrose-density gradients in the presence of Triton X-100. The unique biological and physico-chemical properties of adaGb3 suggest that this analog may be a potent soluble mimic of Gb3, providing a novel concept for developing GSL-derived viral fusion inhibitors.—Mahfoud, R., M. Mylvaganam, C.A. Lingwood, and J. Fantini. A novel soluble analog of the HIV-1 fusion cofactor, globotriaosylceramide (Gb3), eliminates the cholesterol requirement for high affinity gp120/Gb3 interaction. J. Lipid Res. 2002. 43: 1670–1679.

Supplementary key words lipid raft • microdomain • sphingolipid • infection • membrane

The involvement of cellular glycosphingolipids (GSLs) in the attachment and fusion of enveloped viruses has been recognized for a long time (1, 2). In the outer leaflet of the plasma membrane, GSLs can organize into moving platforms, or rafts, onto and into which specific proteins attach within the bilayer. Such rafts play an important role in endocytosis and signal transduction (3–5). This lateral organization probably results from preferential packing of sphingolipids and cholesterol, based on their physico-chemical properties (6, 7). Consequently, sphingolipid-cholesterol rafts are insoluble in the detergent Triton X-100 at 4°C and those detergent-insoluble membranes can be purified by centrifugation on a sucrose-density gradient (3). In the present work, the term raft will be restricted to the sphingolipid/cholesterol-rich domains believed to exist in cell membranes prior to detergent treatment, since detergent-insoluble membranes and rafts are not necessarily identical (7).

Several lines of evidence support the concept that HIV-1 fusion occurs in GSLs-enriched microdomains of the plasma membrane: i) the CD4 receptor interacts with the monosialoganglioside GM3 and with globotriaosylceramide (Gb3), and is accordingly localized in GSL-enriched microdomains (8–11); ii) the HIV-1 surface envelope glycoprotein gp120 binds to several GSLs, including GM3 and Gb3 (10–13); iii) the fusion complex is assembled in GSLs-enriched microdomains (14); iv) removal of cellular cholesterol renders primary cells and cell lines resistant to HIV-1-mediated syncytium formation and to infection by various HIV-1 isolates (15). Moreover, GSLs are necessary to trigger the conformational changes in the envelope glycoprotein required for membrane fusion (16, 17). Among the limited number of GSLs able to promote HIV-1 fusion, Gb3 is certainly the more potent (11, 16, 17).

Pioneer studies have shown that synthetic analogs of

Abbreviations: adaGb3, adamantyl Gb3; adaSGC, adamantyl-sulfatide; DPPC, dipalmitoyl-phosphatidylcholine; GSL, glycosphingolipid; PAPC, palmitoyl-arachidonoyl-phosphatidylcholine; SM, sphingomyelin.

† To whom correspondence should be addressed.
e-mail: jacques.fantini@univ.u-3mrs.fr

Manuscript received 18 April 2002 and in revised form 4 June 2002.
DOI 10.1194/jlr.M200165-JLR200

Copyright © 2002 by Lipid Research, Inc.
This article is available online at http://www.jlr.org
GSL could recognize HIV-1 gp120 and inhibit HIV-1 fusion (18, 19). These studies and others (20–22) have shown that the structure of the glycone of natural and synthetic glycoconjugates can alter the affinity of the GSL-ligand interaction. Although the sugar hydroxyls and substitutions constitute the primary determinants of binding specificity, the glycone structure may promote different intramolecular interactions, particularly at the hydrophilic sugar/hydrophobic ceramide interface (21), to influence GSL-protein interactions. Therefore, there is a crucial need for new GSL analogs with a high affinity for viral ligands (23–26). Ideally, these second generation analogs would mimic the structural organization of GSL in their membrane microdomains, and, at the same time, be sufficiently soluble in water. Since the lipid moiety of GSL is known to modulate ligand binding affinity, developing biologically active soluble GSL is a challenging task (24).

Curve fitting

Experimental data were analyzed with the Origin program, version 3.5 (Microcal software). When indicated, the Boltzmann (x, A1, A2, x0) function producing a sigmoidal curve was used according to the equation:

\[ \frac{(A1-A2)}{[1 + \exp((x-x0)/dx)]} + A2 \]  

(Eq. 1)

Physicochemical properties of Gb3 and adaGb3

The molecular structures of Gb3 and its adamantyl derivative adaGb3 are shown in Fig. 1. The adamantane ring structure provides a condensed, rigid, hydrophobic frame. Pressure-area isotherms of these glycolipids are shown in Fig. 2. Both glycolipids formed stable films. The high compressibility of Gb3 and adaGb3 at all film pressures and the absence of discontinuities in their isotherms show that they exist in the liquid expanded state up to film collapse. Thus, although adaGb3 is highly soluble in water (up to 10 mM), it has retained the property of natural Gb3 to form a compressible film when spread at the air-water interface. Interestingly, the collapse pressure for adaGb3 (52 mN·m⁻¹) was significantly higher than that observed for natural Gb3 (29 mN·m⁻¹). This indicates a higher resistance to compression of adaGb3 versus Gb3, resulting in the formation of a more rigid liquid crystalline phase. This is consistent with the finding that the minimum molecular area for adaGb3 (120 Å²) was larger than that of native Gb3 (80 Å²). At increasing molecular areas (>250 Å²), the surface

EXPERIMENTAL PROCEDURES

Materials

Gb3 was purified from human red blood cells by preparative thin layer chromatography as described previously (11). When indicated, Gb3 purified from human renal epithelium was used (27). AdaGb3 was prepared from purified Gb3 as reported (27). Adamantyl-sulfatide (adaSGC) was prepared by a similar method (28). The multibranched synthetic peptide SPC3 ([GPGRGF]₃-[K]₉-[K]₉-K-BA) (29) was obtained from Eurethics (Paris, France). The HIV-1 (IIIB isolate) surface envelope glycoprotein gp120 was provided by the Medical Research Council (13). Cholesterol, galactosylerceramide (GalCer), sulfatide, sphingomyelin (SM), phosphatidylcholine (PC), and BSA were from Sigma.

Surface pressure measurements

The surface pressure was measured with a fully automated microtensiometer (µTROUGH SX, Kibron Inc. Helsinki, Finland). The apparatus allowed the recording of pressure-area compression isotherms and the kinetics of interaction of a ligand with the monomolecular film using a set of specially designed Teflon troughs. All experiments were carried out in a controlled atmosphere at 20°C ± 1°C. Monomolecular films of Gb3 or adaGb3 (1–2 µg) were spread on pure water subphases (volume of 800 µl) from hexane/chloroform/ethanol solution as described previously (23). After spreading of the film, 5 min was allowed for solvent evaporation. To measure the interaction of HIV-1 gp120, SPC3, or BSA with glycolipid monolayers, the ligand was injected in the subphase with a 10 µl Hamilton syringe, and pressure increases produced were recorded for the indicated time. The data were analyzed with the Filmware 2.5 program (Kibron Inc. Helsinki, Finland). The accuracy of the system under our experimental conditions was ± 0.25 mN·m⁻¹ for surface pressure.

Sucrose-density gradient ultracentrifugation

Dried samples of adaGb3 (100 µg), Gb3 (100 µg), or a mixture of Gb3 (100 µg) and cholesterol (50 µg) were dissolved in 1.5 ml of MES-Triton buffer (pH 7.2, 1% Triton X-100). In some experiments, SM replaced the cholesterol. The solution was vortexed (1 min), sonicated (1 min), heated at 55°C (5 min), and vortexed (1 min). Then 1.5 ml 73% sucrose solution in MES (pH 7.2) was added and gently mixed and allowed to stand at room temperature for 1 h. The mixture was then layered with 2 ml of 30% sucrose containing 10 µg/ml FITC-labeled VT1B, with or without a 50 molar excess of SPC3 peptide. The tube was overlaid successively with 2 ml of 30% sucrose and 3 ml of 5% sucrose and condensed lipid species separated by fractionation ultracentrifugation at 64,000 rpm for 66 h at 4°C. The tubes were photographed under UV and visible illumination. For glycolipid extraction, fractions from the sucrose gradient were applied to C18 SepPak columns, washed extensively with water, and glycolipids eluted with methanol.

RESULTS

Fig. 1. Structural models of Gb3 and adamantyl Gb3 (adaGb3).
pressure for adaGb3, but not Gb3, falls below zero, suggesting that under these conditions, adaGb3 dissolves in the aqueous subphase. This is not seen with adaSGC (28), an adamantyl derivative of sulfatide (3-sulfo-GalCer), demonstrating that adamantane alone is not responsible for this effect (Fig. 2). Finally, the adamantyl derivative of GalCer did not form stable monolayers, showing that the adamantane substitution conferred specific physico-chemical effects in different glycolipids.

A model for the possible organization of the adaGb3 monolayer as a function of surface pressure is shown in Fig. 3. At high surface pressure, adaGb3 is confined to a minimum area of 120 Å². This is considerably greater than the molecular cross-section of adaGb3, indicating that water molecules could be part of an extended structural organization of the interface. Low order aggregates of adaGb3 accumulate as the surface pressure is increased and such aggregates may mimic the arrangement of Gb3 sugars in cholesterol rich lipid microdomains. At lower surface pressures, the solubility and tendency of adaGb3 to monomerize promotes exchange into the bulk solvent to decrease the surface pressure relative to that of water. Reorientation of the sugar moiety to the monolayer interface will increase surface tension and lower surface pressure without dramatically affecting surface energy, i.e. a high surface tension monomeric adaGb3 monolayer.

Interaction of HIV-1 gp120 with Gb3 and adaGb3

Gb3 and adaGb3 were spread at the air-water interface at an initial surface pressure (πi) of 11.5 mN·m⁻¹. HIV-1 gp120 was then added in the aqueous subphase. The interaction of the viral glycoprotein with the glycolipid films was studied by surface pressure measurements. As shown in Fig. 4A, the insertion of gp120 into the film of natural Gb3 occurred after an initial lag phase of 40 min. Similar data were obtained with six different batches of gp120 and Gb3 purified from two distinct pellets of human red blood cells (mean lag phase 33.3 min, range 20–40 min, n = 12). Then the insertion reaction proceeded at an initial rate of 0.05 mN·m⁻¹·min⁻¹ and the equilibrium was reached after 135 min of incubation. A sigmoidal fit obtained with the Boltzman equation is shown (initial pressure A₁, 11.62; final pressure A₂, 17.71; center x₀, 100.70; width dx, 18.0). In contrast, the insertion of gp120 into the film of adaGb3 occurred exponentially without any lag at an initial rate of 0.8 mN·m⁻¹·min⁻¹ (Fig. 4B). In this case, the equilibrium was reached after 15 min of incubation with the viral glycoprotein. The maximal surface pressure increase (Δπmax) induced by gp120 was between 6 and 7 mN·m⁻¹·min⁻¹ for both Gb3 and adaGb3.

To assess the specificity of the gp120-glycolipid interactions, monomolecular films of Gb3 and adaGb3 were prepared at various initial pressures (πi) and the surface pressure increase induced by gp120 on these films was determined after reaching the equilibrium (Fig. 5). For both Gb3 and adaGb3, the compressibility of the monomolecular film was gradually decreased as the initial pressure of the monolayer increased. The influence of the initial surface pressure on the compressibility of the lipid monolayer
Fig. 5. Specificity of interaction between gp120 and Gb3 or adaGb3. The data show the maximal surface pressure increase (Δπmax) reached after injection of HIV-1 gp120 (50 nM) under a monomolecular film of Gb3 (open circle) or adaGb3 (closed circle) at various initial surface pressures. The interaction of gp120 with Gb3 purified from human renal epithelium is also shown (square). demonstrates the high specificity of the interaction as previously established for several other lipids and ligands (30). Similar results were obtained with another batch of Gb3 purified from human renal epithelium (Fig. 5). However, this was not the case with adaSGC, the adamantyl derivative of sulfatide (3-sulfo-GalCer) that interacted to the same level with gp120 at all surface pressures tested in the range of 10–15 mN·m⁻¹ (data not shown). This result demonstrated that the adamantane group alone was not responsible for the specific interaction of the analog with gp120.

Involvement of the V3 loop of gp120 for the interaction with Gb3 and adaGb3

Several lines of evidence suggest the involvement of the V3 domain of gp120 in the recognition of plasma membrane GSLs. In particular, a multivalent synthetic peptide (SPC3) derived from the consensus hexamer motif GPGRAF binds to cell surface GSLs and inhibit HIV-1 fusion in various cell types (29). As shown in Fig. 6A, the insertion of the V3 peptide SPC3 into a monomolecular film of Gb3 occurred after a lag phase of 150 min. The initial rate of insertion was 0.13 mN·m⁻¹·min⁻¹ and the maximal surface pressure increase (Δπmax = 7 mN·m⁻¹) was observed after 200 min of incubation. A sigmoidal fit obtained with the Boltzman equation is shown (initial pressure A1, 8.21; final pressure A2, 16.23; center x0, 166.27; width dx, 12.6). In contrast, the insertion of the V3 peptide into a monomolecular film of adaGb3 proceeded exponentially without any lag phase at an initial rate of 1.16 mN·m⁻¹·min⁻¹ (Fig. 6B). The equilibrium was reached after 15 min of incubation (Δπmax = 6 mN·m⁻¹). The specificity of interaction was assessed by incubating the V3 peptide with monomolecular films of Gb3 and adaGb3 at various initial surface pressures. As shown in Fig. 7, the decreased compressibility of the monolayers when the initial pressure increased demonstrated that the insertion of the peptide was highly specific.

Effect of cholesterol on Gb3-gp120 interaction

Next, we investigated the effects of cholesterol, which is known to condense glycolipids in their natural plasma membrane environment (i.e., membrane rafts) (3, 4), on Gb3-gp120 interaction. To this end, a mixed monolayer consisting of 20% cholesterol and 80% authentic Gb3 from red blood cells (mol/mol) was prepared at the air-water interface. After stabilization of the mixed film at an initial pressure of 9.6 mN·m⁻¹, gp120 (50 nM) was added in the aqueous subphase. The interaction proceeded at an initial rate of 0.9 mN·m⁻¹·min⁻¹ without any lag phase (Fig. 8A). The equilibrium (Δπmax = 5.5 mN·m⁻¹) was reached after 45 min of incubation. Similar data were obtained for higher concentrations of cholesterol (molar ratio of 1:1 between Gb3 and cholesterol), except that in this case the initial rate was 0.15 mN·m⁻¹·min⁻¹ (Table 1). In contrast, gp120 started to interact with a monolayer of pure Gb3 only after 40 min of incubation, as shown in Fig. 4A. The effect of cholesterol was selective for Gb3, since it was not observed with GalCer (Fig. 8B) or SGC (Fig. 8C). In contrast, the presence of cholesterol in a GalCer monolayer slightly reduced gp120 insertion. These data prompted
us to study the interaction of gp120 with a mixed mono-
layer of GalCer and Gb3 (1:1, mol/mol). Under these con-
ditions, the interaction started after a lag phase of 50 min
(initial rate of 0.023 mN·m⁻¹·min⁻¹). The addition of
cholesterol in the monolayer resulted in a marked stimu-
lation of gp120 insertion (suppression of the lag phase,
initial rate of 0.052 mN·m⁻¹·min⁻¹ and higher
Δσmax).

These data are summarized in Table 1.

**Effect of SM on monolayer Gb3-gp120 interaction**

Since SM is an important component of membrane
rafts (4, 5, 7), the effect of this sphingolipid on Gb3-
gp120 interactions was also investigated. As summarized
in Table 1, gp120 interacted with SM monolayers with a
lag phase of 16.7 min. The rate of interaction after this
initial phase was close to the one observed for pure Gb3
(respectively 0.041 and 0.032 mN·m⁻¹·min⁻¹). Surpris-
ingly, the same pattern of interaction was observed when
gp120 was incubated with a mixed monolayer of Gb3 and
SM (1:1, mol/mol). Thus under these conditions, SM did
not induce an improvement of the Gb3-gp120 interaction
as seen with cholesterol. Moreover, the stimulatory effect
of cholesterol was not observed when Gb3 was incorpo-
rated in a monolayer of SM (i.e., when gp120 was incu-
bated with a Gb3-cholesterol-SM monolayer (1:1:1, mol/
mol/mol).

**In natural membranes, glycerophospholipids are also
present within sphingolipid microdomains and may con-
tribute to the binding of protein ligands to lipid rafts.**

For these reasons, we prepared monolayers in which the
sphingolipids were embedded in palmitoyl-arachidonoyl-
phosphatidylcholine (PAPC). Under the present condi-
tions, PAPC did not improve the interaction of gp120
with Gb3. Nevertheless, the stimulatory effect of choles-
terol was still observed when Gb3 was incorporated in a
monolayer of PAPC (data not shown). Similar data were
obtained when dipalmitoyl-phosphatidylcholine (DPPC)
was used.

**Fig. 8.** Effect of cholesterol on gp120-glycosphingolipid (GSL)
interactions. Monolayers of Gb3 (A), GalCer (B), or sulfatide (C)
were prepared in either the absence (closed circle) or presence
(open circle) of cholesterol at an initial surface pressure (πi) of 10
mN·m⁻¹. For mixed monolayers, the molecular ratio was 2:8 and
1:1 for Gb3-cholesterol and GalCer-cholesterol (mol/mol), respec-
tively. HIV-1 gp120 (50 nM) was added in the aqueous subphase un-
derneath the monolayer and the surface pressure was continuously
recorded as a function of time.

**TABLE 1. Interaction between HIV-1 gp120 and various
lipid monolayers**

<table>
<thead>
<tr>
<th>Lipid</th>
<th>Lag Phase</th>
<th>vi</th>
<th>Δσmax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gb3</td>
<td>33.3</td>
<td>0.032</td>
<td>6.1</td>
</tr>
<tr>
<td>GalCer</td>
<td>0</td>
<td>0.148</td>
<td>14.9</td>
</tr>
<tr>
<td>SM</td>
<td>16.7</td>
<td>0.041</td>
<td>7.6</td>
</tr>
<tr>
<td>Gb3 + Chol (1:1)</td>
<td>0</td>
<td>0.150</td>
<td>5.2</td>
</tr>
<tr>
<td>Gb3 + SM (1:1)</td>
<td>16.7</td>
<td>0.041</td>
<td>7.6</td>
</tr>
<tr>
<td>Gb3 + Chol + SM (1:1:1)</td>
<td>17</td>
<td>0.041</td>
<td>6.5</td>
</tr>
<tr>
<td>GalCer + SM (1:1)</td>
<td>0</td>
<td>0.100</td>
<td>9.5</td>
</tr>
<tr>
<td>GalCer + Chol (1:1)</td>
<td>0</td>
<td>0.120</td>
<td>9.3</td>
</tr>
<tr>
<td>GalCer + Gb3 (1:1)</td>
<td>50</td>
<td>0.023</td>
<td>5.3</td>
</tr>
<tr>
<td>GalCer + Gb3 + Chol (1:1:1)</td>
<td>0</td>
<td>0.052</td>
<td>11.8</td>
</tr>
</tbody>
</table>

Monolayers were prepared at an initial surface pressure of 10
mN·m⁻¹. HIV-1 gp120 (50 nM) was added in the aqueous subphase un-
derneath the monolayer and the surface pressure was continuously re-
corded as a function of time. The initial rate of interaction (vi) and the
maximal surface pressure increase (∆σmax) were determined with the
same batch of gp120. The results are the mean of three independent
determinations (SD < 15%).
Recovery of adaGb3 into Triton X-100-resistant condensed lipid structures

Since adaGb3 eliminates the lag phase and cholesterol requirement for optimal gp120/Gb3 interaction, we investigated whether adaGb3 was able to form Triton resistant dense lipid aggregates, variously characterized as “lipid rafts,” “detergent resistant microdomains,” “detergent insoluble microdomains,” or “glycolipid enriched microdomains,” typically separated on a discontinuous sucrose ultracentrifugation gradient after cell extraction (7). To facilitate visualization of any such structures, we centrifuged the lipids through a layer of FITC-VT1B.

When adaGb3 alone was centrifuged, adaGb3/VT1B complexes were concentrated in a single band corresponding to a low density fraction (Fig. 9, lane 1), i.e., where “raft-like” structures are expected to migrate (7). In contrast, native Gb3 did not form an FITC-VT1B labeled dense band (Fig. 9, lane 2). For the native glycolipid, a condensed lipid band was obtained only when Gb3 was mixed with cholesterol (Fig. 9, lane 3), consistent with the results of the monolayer study. SM was less effective than cholesterol to promote condensed Gb3 lipid structures, monitored under visible light but due to quenching (resulting from the basic charge?) could not be used with FITC-VT1B. In the presence of excess SPC3, FITC-VT1B binding to the adaGb3 band was competed out (Fig. 9, lane 4 vs. 5). The adaGb3 band was still evident under visible light (not shown).

Analysis of the Gb3 content of the sucrose gradient for the Gb3/cholesterol mixture confirmed the presence of Gb3 within the VT1B labeled condensed lipid band (Fig. 10A). The Gb3 content of this band was dependent on the cholesterol concentration (Fig. 10B). Inclusion of SM increased the Gb3 content markedly (Fig. 10C) but VT1B binding was not increased (not shown).

Overall these data suggest that: i) adaGb3 can spontaneously form condensed, detergent resistant aggregates as Gb3 does only in the presence of cholesterol, ii) functionally, SM cannot substitute for cholesterol, iii) SM has no additive effect in terms of VT1/Gb3 + cholesterol binding, and iv) these molecular structures are recognized by both VT1B and the multibranched V3 peptide SPC3.

Lack of interaction between BSA and adaGb3

One potential drawback of synthetic soluble analogs of lipids is that they may bind to serum albumin, resulting in a total loss of biological activity in presence of serum. In order to study this possibility, monolayers of adaGb3 were prepared at the air-water interface and BSA was injected in the aqueous subphase. As shown in Fig. 11, serum albumin did not significantly affect the surface pressure of the monomolecular film. Furthermore, when the multibranched V3 peptide SPC3 was injected in the subphase in presence of a 5-molar excess of serum albumin, its interaction with adaGb3 was not affected. Thus, serum albumin did not bind to adaGb3 and did not prevent the binding of adaGb3 to the V3 peptide.

DISCUSSION

It is now well established that a wide variety of pathogens, including both bacteria and viruses, use GSLs as binding sites on the cell surface of host cells (1, 2, 11, 23, 31–33). Accordingly, there is a considerable interest in developing synthetic analogs of GSLs as specific inhibitors of glycolipid-pathogen interactions (24–26). The complex role played by the lipid moiety in glycolipid interactions has delayed the development of such analogs which have sufficient water solubility and, in the same time, mimic the structural and functional organization of GSLs in the...
plasma membrane. The structure of the lipid moiety itself, particularly of the interface region, and the membrane microenvironment may play a role in the presentation of the carbohydrate for ligand binding, such that the sugar moiety alone may be without receptor activity (34). These considerations were the basis for the development of adamantyl conjugates of Gb3 (27), the glycolipid receptor of the \textit{Escherichia coli} derived verotoxin (32). Verotoxin/Gb3 interaction is highly dependent on the lipid moiety of Gb3 to present the sugar moiety for binding (22, 35). AdaGb3 was designed as an attempt to mimic this effect in solution (27). In this class of glycolipid analogs, the fatty acid chain is replaced by rigid three-dimensional hydrocarbon frames, i.e., adamantane. The resulting adaGb3 analog showed a markedly increased solubility in water compared with natural Gb3, and a 1,000-fold enhanced inhibitory activity in a Gb3-verotoxin binding assay, as compared with the free sugar (27).

Since Gb3 is recruited by HIV-1 gp120 during the formation of the HIV-1 fusion complex involving the chemokine receptor CXCR4 (16, 36), and the GSL aglycone is crucial for gp120 binding (37), it was of great interest to analyze the interaction of gp120 with adaGb3. Using the Langmuir film balance technology and a microtensiometer specially designed for measuring lipid-protein interactions, we found that gp120 specifically binds to adaGb3 far more rapidly than to natural Gb3. The analysis of Gb3-gp120 interactions was performed with two different batches of authentic Gb3 purified from human renal epithelium or human erythrocytes by two independent laboratories (those of J. Fantini and C. A. Lingwood), and similar results were obtained. In both cases, the insertion of gp120 into a monomolecular film of Gb3 required a lag phase that corresponds to a binding step. Indeed, one particularity of the Langmuir method is that the surface pressure is increased only when the protein penetrates the film, resulting in the lateral moving of lipid molecules (30). The absence of lag phase during the interaction between gp120 and adaGb3 suggests that the binding step is almost instantaneous, which is in agreement with the reported 1,000-fold enhanced affinity of verotoxin for adaGb3 compared with the lipid free Gb3 oligosaccharide. It was considered that the adamantane group might prevent extensive lamellar packing in aqueous systems, while duplicating in part the hydrophobic effect of the lipid moiety.

Fig. 10. Gb3 content of condensed lipid structures. Gb3/cholesterol/triton mixtures were subjected to discontinuous sucrose gradient ultracentrifugation as in Fig. 9 and fractions were collected and analyzed for Gb3 content by thin layer chromatography and orcinol spray for carbohydrate. A: Gb3/cholesterol 2:1 (μg/μg) fractionated from the top of the gradient (lanes 2–8), Lane 1 renal Gb3 standard; lane 4 represents the fraction containing the FITC-VT1B labeled band in Fig. 9 and contains most of the Gb3. The slower migrating species is residual sucrose. B: Gb3/cholesterol 50:1 (μg/μg) lanes 2–4; Gb3/cholesterol 2:1 (μg/μg) lanes 5–7. Lanes 2–4 and lanes 5–7 are the equivalent to lanes 2–4 in A. Increasing the cholesterol content increases the Gb3 forming condensed lipid structures. C: Each lane represents the fraction containing the condensed lipid structure (A, lane 4). Lane 1 renal Gb3 standard; lane 2 Gb3/cholesterol 2:1 (μg/μg), lane 3 Gb3/cholesterol-sphingomyelin (SM) 2:1:1 (μg/μg/μg), lane 4 Gb3/cholesterol-phosphatidylcholine 2:1:1 (μg/μg/μg) lane 5 SM-cholesterol-phosphatidylcholine 1:1:1 (no band on the gradient is seen). Gb3 within the condensed lipid structure is increased following the inclusion of SM.

Fig. 11. Bovine serum albumin does not affect the interaction of the V3 peptide with adaGb3. A monolayer of adaGb3 was prepared at the air-water interface at an initial surface pressure (σ) of 10 mN·m\(^{-1}\). The variations in the surface pressure (Δσ, expressed in mN·m\(^{-1}\)) were recorded as a function of time after addition of 500 nM BSA (BSA, closed circle), 100 nM V3 peptide SPC3 (square), or a mixture of BSA + SPC3 (500 and 100 nM, respectively, open circle) in the aqueous subphase underneath the monolayer.

on receptor function. This might explain the increased molecular area of the adaGb3 as compared with Gb3 (Fig. 2). The present results indicate that adaGb3 excels at presenting an appropriate Gb3 receptor format for gp120 recognition. The increased surface pressure at reduced molecular areas is suggestive of reduced compressibility and greater rigidity. The lag time observed for gp120/Gb3 binding and the fact that the saturation binding of gp120 to Gb3 and adaGb3 are essentially the same, suggests that Gb3 may have to undergo a lateral rearrangement, e.g., to form microdomains to efficiently bind gp120. Initially, the frequency of such domains is low but accumulate cooperatively upon gp120 binding. This cooperativity is less pronounced for the V3 domain alone (i.e., the synthetic V3 peptide) giving a longer lag phase for binding.

Moreover, the initial rate of insertion of gp120 is about 10-fold higher in the monolayer of adaGb3 compared with Gb3. Similar results were obtained with a synthetic V3 peptide, in agreement with previous reports demonstrating the involvement of the V3 domain of gp120 in glycolipid recognition (13, 29). Most importantly, these data show that the enhanced affinity of adaGb3 for verotoxin (27) can be extrapolated to HIV-1 gp120 and a synthetic V3 peptide. Therefore, adamantyl derivatives of glycolipids provide invaluable tools for studying glycolipid receptor function. In addition, one should note that in our experimental conditions, adaGb3 formed a stable monomolecular film at the air-water interface, and that gp120 insertion did not result in the collapse of the film. This suggests that the interactions between adaGb3 molecules are strong enough to maintain the cohesion of the film despite the high water solubility of the analog. Hence, the experimental design used in the present study is valid for measuring the characteristics of adaGb3 binding to HIV-1 gp120.

The physicochemical properties of adaGb3 may explain why it exhibits such an enhanced affinity for various ligands. Similar effects are not seen with ada-SGC, indicating that the adamantane frame does not play a direct role. The fact that sulfatide is bound by gp120 (38) but ada-SGC monolayers are not affected by gp120 indicates a distinction between binding and membrane fusion. This distinction was previously highlighted by the finding that increasing the cellular SGC content increased HIV binding but inhibited fusion (39). The selective role of Gb3 in HIV cell fusion (16) verifies the present monolayer system as a model of this property. On the other hand, the binding of cholera toxin to GM1 only when presented as condensed complexes in artificial cholesterol/phospholipid membranes (40) is consistent with the idea that the presentation of GSLs for binding can be radically affected by the receptor density within membrane microdomains or rafts. The behavior of monomolecular films of adaGb3 at the air-water interface showed that the replacement of the fatty acid chain with adamantane resulted in a more rigid monolayer with decreased compressibility (Fig. 2) despite the markedly increased water solubility of this Gb3 derivative (27). This latter property likely results in the reduction of the surface pressure below that of water at increased surface areas due to the reorientation of the monomer as suggested in Fig. 3. Despite a similar minimum molecular volume, ada-SGC monolayers, unlike adaGb3, were unable to resist the increased surface pressure as the surface area was reduced and collapsed. This more rigid structure may mimic the carbohydrate organization of natural Gb3 in membrane rafts, as anticipated in a recent report (27). AdaSGC may not form equivalent structures. Indeed, the head group charge of sulfatide may constrain incorporation into condensed rafts, which may in turn relate to its lack of a role in HIV cell fusion (39). Consistent with this hypothesis, we observed that cholesterol, which is known to condense glycolipids in membrane rafts (5, 40), increased the initial rate of gp120 insertion in a monolayer of authentic Gb3 and abrogated the lag phase. Interestingly, this effect of cholesterol was selective for Gb3, since it was not observed for GalCer, or SGC, GSLs with a marked affinity for HIV-1 gp120. The lack of effect of cholesterol on gp120-GalCer interaction may be explained by the low condensing effect of cholesterol on GalCer monolayers (41). In contrast, the more bulky saccharide chain of Gb3 (Fig. 1) may impair the stacking of the ceramide moiety in the monolayer, allowing the insertion of cholesterol between glycolipid molecules. This would optimize the steric presentation and recognition of the glycolipid (42), resulting in an enhanced affinity for gp120. Direct effects of cholesterol on receptor function have been reported previously (43). Another interesting finding is that gp120 interacts with mixed monolayers of GalCer and Gb3, with a lag phase of 50 min. Thus in this mixture, the gp120 insertion parameters are characteristic of Gb3, not GalCer. These data are in agreement with our hypothesis that the lag phase corresponds to a reorganization of the monolayer leading to an optimal presentation of the glycolipid for gp120 binding. Cholesterol stimulates this process as demonstrated by the rapid and efficient interaction observed between gp120 and a GalCer/Gb3/cholesterol film (Table 1). It is possible that the high cholesterol content of the plasma membrane as opposed to the endomembrane system plays a modulatory role in relative gp120-glycolipid recognition during the HIV infectious cycle. Finally, although abundantly expressed in lipid rafts, SM (SM) does not seem to affect the presentation of Gb3, since its presence in the monolayer did not improve gp120 binding (Table 1). SM did increase the Gb3 content of the dense fraction of the sucrose gradient consistent with a Gb3/SM interaction characteristic of lipid rafts (7), but VT1B binding was not increased (SM quenched FITC-VT1B which therefore could not be used). However, this fraction contained larger aggregates limiting interpretation. SM via interaction with cholesterol (44) may alter the Gb3 domain organization when spread together at the interface. In the sucrose gradients, Gb3 found in the condensed lipid fraction in the presence of cholesterol was increased several-fold by inclusion of SM but VT1B binding was not increased, suggesting that Gb3-SM dense complexes are formed but not bound by VT1B. The interaction of gp120 with various mixtures of Gb3, GalCer, SM, and cholesterol was not affected by the presence of PC (either PAPC or DPPC) in the reconstituted monolayers and PC had no effect on the Gb3 content of cholesterol containing
Triton resistant condensed structures on a sucrose gradient. Taken together, these data strongly suggest that cholesterol (and other lipid species) is required for optimal binding of gp120 to Gb3 microdomains. This is in agreement with the recent demonstration that the formation of "raft domains" within reconstituted membranes critically depends on the cholesterol content (40) and that host membrane cholesterol is required for cellular infection by HIV-1 (15).

These conclusions are also supported by the sucrose ultracentrifugation studies. In solution, Gb3 formed Triton X-100 resistant low-density condensed lipid structures when mixed with cholesterol, but not alone. In contrast, adaGb3 could form similar structures alone, which strongly supports the view that this analog may mimic the typical organization of Gb3/cholesterol complexes in detergent-insoluble microdomains. In such microdomains, the presentation of the Gb3 carbohydrate may, due to changes in the interface, be optimal for gp120 binding and subsequent insertion, similar to cholera toxin/GM1 binding (40). We propose that this effect is mimicked by adaGb3.

One important issue raised by the present study is the specificity of interaction between Gb3/adaGb3 and HIV-1 gp120. Indeed, gp120 also interacts with GalCer and sulfatide (39). However, the adamantyl derivative of GalCer could not form stable monolayers at the air-water interface, whereas adaSGC, which could form monolayers (Fig. 2), was not recognized by gp120 (Fig. 8C). Thus, among the adamantyl derivatives of GSL receptors for HIV-1 gp120, adaGb3 has unique physico-chemical and binding properties. GM1 have been shown to inhibit HIV-1 infectivity in vitro, but the action of this ganglioside was to prevent cell surface expression of CD4 (45). Indeed, the interaction of gp120 with GM1 is very weak compared with GalCer or Gb3 (11). Moreover, subsequent addition of fetal calf serum or bovine and human serum albumin blocked GM1 action on CD4 expression, most likely through the formation of ganglioside-albumin complexes (45). For these reasons, we tested the potential effect of serum albumin on adaGb3 monolayers. We found that BSA did not bind to adaGb3 and did not affect the interaction of the gp120 V3 peptide with adaGb3.

In conclusion, the results of the present study showed that semi-synthetic analogs of GSLs like adaGb3 may functionally mimic Gb3 microdomains, providing a new class of molecular tools for studying the role of glycolipids and lipid rafts in HIV-1 fusion (46, 47) and other biological processes (32). To the best of our knowledge, our study presents the first experimental evidence that condensed lipid structures can be formed in absence of cholesterol by a synthetic analog of a glycolipid receptor. From a therapeutic point of view, disrupting gp120-glycolipid interactions by such glycolipid derivatives would obviate the problem of resistance mutants selected by current antiretroviral treatments (48, 49) and may open a new route for controlling HIV-1 replication in infected individuals (24).

This work was supported by Canadian Institutes of Health Research grant no. MT13073 (C.A.L.).

REFERENCES


35. Kiarash, A., B. Boyd, and C. A. Lingwood. 1994. Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different glo-


